Bicara Therapeutics is a biotechnology company focused on developing innovative cancer therapies. It was founded in 2018 and is based in Cambridge, Massachusetts. The firm specializes in bispecific antibody technology. This approach targets multiple pathways in cancer cells. It aims to enhance treatment efficacy and reduce side effects. Bicara's research is significant in the evolving landscape of cancer immunotherapy.
Biocon founder and chairperson Kiran Mazumdar-Shaw announced on 5 May 2026 a phased, five-year leadership transition plan naming her niece, Claire Mazumdar, as her successor. Claire Mazumdar, aged...
